Clinical Trials Logo

Clinical Trial Summary

Atopic dermatitis is a chronic disease characterized by itching and eczematous lesions. In adults, eczema commonly localizes to the hands or feet. Several studies have implicated bacterial contamination, especially with Staphylococcus aureus (S. aureus), to be a factor in atopic dermatitis, as infection with this bacteria correlates with disease severity. No trial to date has investigated how to treat S. aureus infection in adults with hand or hand/foot dermatitis. Using retapamulin ointment in the nose and on the hands or hands/feet, the investigators expect to have a significant clearance rate of s. aureus infection. The investigators believe that treating the bacterial infection along with treating the condition with a topical corticosteroid will significantly decrease the severity of hand/foot dermatitis in our study population.


Clinical Trial Description

Primary Study Objectives: 1. To evaluate the efficacy of retapamulin 1% ointment with clobetasol propionate 0.05% foam versus vehicle ointment with clobetasol propionate 0.05% foam as a treatment regimen for hand or hand/foot atopic dermatitis. 2. To evaluate the incidence of intranasal and hand/foot S aureus carriage rates in subjects with hand/foot atopic dermatitis via cultures of an anterior nare and the most severely graded target lesion of the hand/foot dermatitis. 3. To evaluate the incidence of mupirocin-resistance and methicillin-resistance in S aureus isolates in subjects with hand/foot atopic dermatitis via cultures of an anterior nare and the most severely graded target lesion of the hand/foot dermatitis. Primary and secondary endpoints will be analyzed by appropriate statistical models by a qualified statistician. Any results of this pilot study will be treated as exploratory and hypothesis generating. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01591785
Study type Interventional
Source Icahn School of Medicine at Mount Sinai
Contact
Status Completed
Phase N/A
Start date January 2012
Completion date August 2012

See also
  Status Clinical Trial Phase
Completed NCT00576550 - A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema Phase 4
Completed NCT00404196 - LEO19123 Cream in the Treatment of Hand Eczema Phase 2
Completed NCT05763914 - A 24-week Single-blind Trial of Prevention of Hand Eczema in Cleaners N/A
Recruiting NCT03026946 - Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema Phase 3
Recruiting NCT03026907 - Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema Phase 3
Completed NCT00488241 - Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema Phase 4
Active, not recruiting NCT05906628 - Topical Ruxolitinib Evaluation in Chronic Hand Eczema Phase 2
Terminated NCT01826630 - A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema N/A
Recruiting NCT04449575 - Hand Eczema in the Health Care Sector
Withdrawn NCT05219864 - Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 Phase 3
Completed NCT00826592 - Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis N/A
Completed NCT02664805 - Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema Phase 2
Completed NCT05471934 - Satisfaction Survey - Cicaplast Mains
Active, not recruiting NCT04512339 - Dupilumab in Severe Chronic Hand Eczema Phase 2
Completed NCT04375410 - Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic